Daily Cardiology Research Analysis
Analyzed 298 papers and selected 3 impactful papers.
Summary
Three studies advance arrhythmia care and risk stratification: an observational comparison shows nanosecond pulse field ablation for paroxysmal atrial fibrillation can be performed under conscious sedation with minimal muscle response and outcomes comparable to microsecond PFA; a multicenter cohort identifies age-corrected QRS duration as a prognostic marker in SCN5A-E1784K overlap sodium channel disease; and a meta-analysis supports cardiac MRI markers (late gadolinium enhancement, mitral annular disjunction, systolic curling) for arrhythmic risk in mitral valve prolapse.
Research Themes
- Pulsed field ablation feasibility and patient-centered workflow
- Genotype-phenotype risk markers in inherited arrhythmia syndromes
- CMR-based prognostic imaging in mitral valve prolapse
Selected Articles
1. Cardiac Magnetic Resonance for the Prediction of Arrhythmic Events in Mitral Valve Prolapse: A Systematic Review and Meta-analysis.
Across 15 studies (n=1,994), CMR markers including LGE, MAD, and systolic curling were each significantly associated with increased arrhythmic events in MVP; pooled risk for LGE was RR 1.8 (95% CI 1.4–2.2). The synthesis supports the incremental prognostic role of CMR over conventional assessment for risk stratification in MVP.
Impact: Provides quantitative evidence consolidating CMR biomarkers for arrhythmic risk in MVP, informing imaging-led risk stratification and potential preventive strategies.
Clinical Implications: In MVP patients, CMR assessment for LGE, MAD, and systolic curling can refine selection for intensified monitoring, ambulatory rhythm surveillance, or consideration of early electrophysiology referral.
Key Findings
- Meta-analysis of 15 studies (n=1,994) showed each of LGE, MAD, and systolic curling was associated with higher arrhythmic event risk.
- Pooled risk for LGE was RR 1.8 (95% CI 1.4–2.2), supporting its prognostic significance.
- Synthesis supports CMR as an adjunct to improve arrhythmic risk stratification in MVP.
Methodological Strengths
- Systematic synthesis across 15 studies enhances statistical power
- Focus on predefined CMR biomarkers improves construct validity
Limitations
- Abstract truncation limits access to full pooled estimates for MAD and systolic curling
- Heterogeneity in imaging protocols and endpoint definitions across included studies
Future Directions: Prospective, standardized CMR protocols with adjudicated arrhythmic endpoints and decision-impact studies to test CMR-guided management strategies in MVP.
Cardiac magnetic resonance (CMR) has gained ground in the assessment of mitral valve prolapse (MVP) patients. In this meta-analysis we assessed the prognostic value of key CMR-derived imaging biomarkers -late gadolinium enhancement (LGE), mitral annular disjunction (MAD) and systolic curling- in patients with MVP. We also aimed to define the clinical and imaging features of patients with LGE on CMR. 15 studies comprising 1,994 patients with MVP were included in this systematic review. All three MVP-related imaging biomarkers were significantly associated with increased risk of arrhythmic events (pooled RRs: 1.8, 95% CI: 1.4-2.2, I
2. Ventricular conduction is a marker for arrhythmic risk in SCN5A-E1784K overlap sodium channel disease.
In 231 SCN5A-E1784K carriers, lethal events occurred in 6% and cardiac events in 19%. Longer PR interval and QRS duration associated with lethal events, while only QRS duration associated with overall cardiac events; after multiple testing correction, age-adjusted QRS (rQRS) remained the sole predictor of event-free survival.
Impact: Identifies a simple, age-adjusted ECG conduction marker (rQRS) that stratifies inherited arrhythmic risk across the E1784K overlap phenotype.
Clinical Implications: Incorporating rQRS into surveillance may personalize preventive strategies (e.g., intensified monitoring, therapy selection) for SCN5A-E1784K carriers beyond syndrome labels.
Key Findings
- Among 231 SCN5A-E1784K subjects, 14 (6%) had lethal events and 45 (19%) had cardiac events.
- PR interval and QRS duration associated with lethal events; only QRS duration associated with cardiac events.
- After multiple-testing correction, age-adjusted QRS (rQRS) was the sole predictor of event-free survival.
Methodological Strengths
- Multicenter cohort across Europe, USA, and Japan increases generalizability
- Age-corrected ECG metrics and multiple-testing correction strengthen inference
Limitations
- Retrospective design limits causal inference
- Potential ascertainment bias in event capture and phenotyping
Future Directions: Prospective validation of rQRS thresholds and integration into genotype-specific risk algorithms; exploration of conduction-modifying therapies.
BACKGROUND AND AIMS: SCN5A-E1784K (c.5350G>A) is the most common variant associated with the long QT (LQTS) and Brugada syndromes (BrS). It can manifest variably as LQTS, BrS and/or conduction disorders. This presents a challenge for risk stratification. We aimed to describe clinical and ECG characteristics and identify risk markers that associate with arrhythmic events. METHODS: We undertook a retrospective observational multicentre study of a large cohort of 231 subjects with SCN5A-E1784K from Europe, USA and Japan. Comprehensive demographic and clinical data, including initial presentation ECG and follow-up, were collected. 'Lethal events' were defined as sudden death, non-fatal cardiac arrest, and documented sustained VT or VF. 'Cardiac events' were defined as arrhythmic syncope plus any lethal events. Clinical characteristics and ECG parameters corrected for age were investigated for association with lethal and/or cardiac events. RESULTS: Fourteen (6%) subjects experienced a lethal event and 45 (19%) a cardiac event. PR interval and QRS duration were associated with lethal and cardiac events. In multivariable models, both PR interval and QRS duration were associated with lethal events but only QRS duration was associated with cardiac events. Only age-corrected QRS (rQRS) was associated with lethal and cardiac event-free survival from birth after correction for multiple testing. CONCLUSION: Ventricular myocardial conduction appears likely to play a role in the risk of arrhythmic events in patients with SCN5A-E1784K. This provides an important opportunity for the personalisation of management and has the potential to guide preventative therapies.
3. Nanosecond and Microsecond Pulse Field Ablation for Paroxysmal Atrial Fibrillation: Muscle Response, Procedural Safety, and 6-Month Outcomes.
In 151 paroxysmal AF patients, nanoPFA under conscious sedation achieved universal PVI/SVCI without device-related complications, with absent/slight muscle contraction in ~91% and no severe pain; 87.7% preferred conscious sedation. Six-month arrhythmia-free survival was comparable to microPFA, including after propensity matching.
Impact: Demonstrates feasibility of a conscious-sedation nanoPFA workflow with low muscle response and patient-reported comfort while maintaining arrhythmia outcomes comparable to microPFA.
Clinical Implications: Centers may consider nanoPFA with conscious sedation to streamline AF ablation pathways, reduce anesthesia reliance, and improve patient experience without compromising short-term efficacy.
Key Findings
- Universal PVI/SVCI and no device-related complications in both groups.
- NanoPFA showed absent/slight muscle contraction in 91.3% and no severe pain; 87.7% preferred conscious sedation.
- Six-month freedom from atrial tachyarrhythmia: nanoPFA 91.8% vs microPFA 83.9% (P=0.57); similar after propensity matching.
Methodological Strengths
- Prospective assessments of patient-reported outcomes (VAS, Likert) alongside clinical endpoints
- Propensity score matching as sensitivity analysis to address confounding
Limitations
- Nonrandomized design with potential selection bias
- Short follow-up (6 months) limits assessment of lesion durability
Future Directions: Randomized trials comparing nanoPFA vs microPFA under standardized anesthesia strategies with longer follow-up and transesophageal endoscopy/CMR safety substudies.
BACKGROUND: Nanosecond pulse field ablation (nanoPFA) is an emerging nonthermal modality that may reduce muscle contractions and enable atrial fibrillation (AF) ablation under conscious sedation. OBJECTIVE: The aim of the study was to compare the muscle response, safety, and 6-month outcomes between nanoPFA and microsecond PFA (microPFA). METHODS: Patients with symptomatic paroxysmal AF underwent nanoPFA under conscious sedation or microPFA under general anesthesia. In the nanoPFA group, muscle contraction, pain (Visual Analogue Scale, VAS), and patient experience (Likert scale questionnaire) were assessed. Outcomes were evaluated at 3 and 6 months. Propensity score matched (PSM) was performed as sensitivity analysis. RESULTS: Among 151 patients (60.2 ± 11.4 years, 32.5 % female), 57 received nanoPFA and 94 underwent microPFA. Pulmonary vein and superior vena cava isolation was completed in all, with no device-related complications. During nanoPFA, muscle contraction was absent in 43.9 %, slight in 47.4 %, and severe in 8.8%, most frequently at the right superior pulmonary vein. Most patients reported mild/no discomfort (VAS 0-4: 71.9% [41/57]); none reported severe pain, and 87.7 % preferred conscious sedation. Six-month Kaplan-Meier freedom from any atrial tachyarrhythmia was 91.8 % with nanoPFA and 83.9 % with microPFA (log-rank P = 0.57); after PSM, 6-month freedom remained similar between groups (90.0 % vs. 88.9 %, log-rank P = 0.56). CONCLUSIONS: NanoPFA performed under conscious sedation provides comparable safety and similar 6-month arrhythmia outcomes to microPFA under general anesthesia, with minimal pain and muscle responses, supporting the feasibility of a conscious-sedation workflow in our center.